Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Colorcon
Johnson and Johnson
McKesson

Last Updated: May 22, 2022

Investigational Drug Information for Bimagrumab


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Bimagrumab?

Bimagrumab is an investigational drug.

There have been 7 clinical trials for Bimagrumab. The most recent clinical trial was a Phase 3 trial, which was initiated on November 2nd 2015.

The most common disease conditions in clinical trials are Myositis, Inclusion Body, Myositis, and Sarcopenia. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are two US patents protecting this investigational drug and eighteen international patents.

Recent Clinical Trials for Bimagrumab
TitleSponsorPhase
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 DiabetesNovartis PharmaceuticalsPhase 2
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203Novartis PharmaceuticalsPhase 3
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core StudyNovartis PharmaceuticalsPhase 2

See all Bimagrumab clinical trials

Clinical Trial Summary for Bimagrumab

Top disease conditions for Bimagrumab
Top clinical trial sponsors for Bimagrumab

See all Bimagrumab clinical trials

US Patents for Bimagrumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bimagrumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
Bimagrumab See Plans and Pricing Administration of bimagrumab for improving muscle mass and function after hip fracture surgery Novartis AG (Basel, CH) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bimagrumab

Drugname Country Document Number Estimated Expiration Related US Patent
Bimagrumab Australia AU2015249396 2034-04-24 See Plans and Pricing
Bimagrumab Australia AU2018200537 2034-04-24 See Plans and Pricing
Bimagrumab Brazil BR112016023979 2034-04-24 See Plans and Pricing
Bimagrumab Canada CA2944842 2034-04-24 See Plans and Pricing
Bimagrumab Chile CL2016002679 2034-04-24 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Colorcon
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.